252 related articles for article (PubMed ID: 33951891)
1. DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome.
Todoerti K; Ronchetti D; Favasuli V; Maura F; Morabito F; Bolli N; Taiana E; Neri A
Haematologica; 2022 Apr; 107(4):921-932. PubMed ID: 33951891
[TBL] [Abstract][Full Text] [Related]
2.
Favasuli VK; Ronchetti D; Silvestris I; Puccio N; Fabbiano G; Traini V; Todoerti K; Erratico S; Ciarrocchi A; Fragliasso V; Giannandrea D; Tumiatti F; Chiaramonte R; Torrente Y; Finelli P; Morelli E; Munshi NC; Bolli N; Neri A; Taìana E
Haematologica; 2024 Jan; 109(1):231-244. PubMed ID: 37439377
[TBL] [Abstract][Full Text] [Related]
3.
Ohguchi Y; Ohguchi H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835493
[TBL] [Abstract][Full Text] [Related]
4. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.
Weißbach S; Langer C; Puppe B; Nedeva T; Bach E; Kull M; Bargou R; Einsele H; Rosenwald A; Knop S; Leich E
Br J Haematol; 2015 Apr; 169(1):57-70. PubMed ID: 25521164
[TBL] [Abstract][Full Text] [Related]
5. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Fabris S; Tonon G; Segalla S; Cifola I; Pinatel E; Tassone P; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(28):26129-41. PubMed ID: 26305418
[TBL] [Abstract][Full Text] [Related]
6. DIS3 shapes the RNA polymerase II transcriptome in humans by degrading a variety of unwanted transcripts.
Szczepińska T; Kalisiak K; Tomecki R; Labno A; Borowski LS; Kulinski TM; Adamska D; Kosinska J; Dziembowski A
Genome Res; 2015 Nov; 25(11):1622-33. PubMed ID: 26294688
[TBL] [Abstract][Full Text] [Related]
7. Exonuclease domain mutants of yeast DIS3 display genome instability.
Milbury KL; Paul B; Lari A; Fowler C; Montpetit B; Stirling PC
Nucleus; 2019 Dec; 10(1):21-32. PubMed ID: 30724665
[TBL] [Abstract][Full Text] [Related]
8. The ribonuclease Dis3 is an essential regulator of the developmental transcriptome.
Hou D; Ruiz M; Andrulis ED
BMC Genomics; 2012 Aug; 13():359. PubMed ID: 22853036
[TBL] [Abstract][Full Text] [Related]
9. Loss of ribonuclease DIS3 hampers genome integrity in myeloma by disrupting DNA:RNA hybrid metabolism.
Gritti I; Basso V; Rinchai D; Corigliano F; Pivetti S; Gaviraghi M; Rosano D; Mazza D; Barozzi S; Roncador M; Parmigiani G; Legube G; Parazzoli D; Cittaro D; Bedognetti D; Mondino A; Segalla S; Tonon G
EMBO J; 2022 Nov; 41(22):e108040. PubMed ID: 36215697
[TBL] [Abstract][Full Text] [Related]
10. RNA-regulatory exosome complex confers cellular survival to promote erythropoiesis.
Mehta C; Fraga de Andrade I; Matson DR; Dewey CN; Bresnick EH
Nucleic Acids Res; 2021 Sep; 49(16):9007-9025. PubMed ID: 34059908
[TBL] [Abstract][Full Text] [Related]
11. The 3'-5' exoribonuclease Dis3 regulates the expression of specific microRNAs in Drosophila wing imaginal discs.
Towler BP; Jones CI; Viegas SC; Apura P; Waldron JA; Smalley SK; Arraiano CM; Newbury SF
RNA Biol; 2015; 12(7):728-41. PubMed ID: 25892215
[TBL] [Abstract][Full Text] [Related]
12. The 3' to 5' Exoribonuclease DIS3: From Structure and Mechanisms to Biological Functions and Role in Human Disease.
Robinson SR; Oliver AW; Chevassut TJ; Newbury SF
Biomolecules; 2015 Jul; 5(3):1515-39. PubMed ID: 26193331
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target.
Tomecki R; Drazkowska K; Kucinski I; Stodus K; Szczesny RJ; Gruchota J; Owczarek EP; Kalisiak K; Dziembowski A
Nucleic Acids Res; 2014 Jan; 42(2):1270-90. PubMed ID: 24150935
[TBL] [Abstract][Full Text] [Related]
14. Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression.
de Groen FL; Krijgsman O; Tijssen M; Vriend LE; Ylstra B; Hooijberg E; Meijer GA; Steenbergen RD; Carvalho B
Genes Chromosomes Cancer; 2014 Apr; 53(4):339-48. PubMed ID: 24478024
[TBL] [Abstract][Full Text] [Related]
15.
Boyle EM; Ashby C; Tytarenko RG; Deshpande S; Wang H; Wang Y; Rosenthal A; Sawyer J; Tian E; Flynt E; Hoering A; Johnson SK; Rutherford MW; Wardell CP; Bauer MA; Dumontet C; Facon T; Thanendrarajan S; Schinke CD; Zangari M; van Rhee F; Barlogie B; Cairns D; Jackson G; Thakurta A; Davies FE; Morgan GJ; Walker BA
Clin Cancer Res; 2020 May; 26(10):2422-2432. PubMed ID: 31988198
[TBL] [Abstract][Full Text] [Related]
16. The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA.
Segalla S; Pivetti S; Todoerti K; Chudzik MA; Giuliani EC; Lazzaro F; Volta V; Lazarevic D; Musco G; Muzi-Falconi M; Neri A; Biffo S; Tonon G
Nucleic Acids Res; 2015 May; 43(10):5182-93. PubMed ID: 25925570
[TBL] [Abstract][Full Text] [Related]
17. Noncoding RNA processing by DIS3 regulates chromosomal architecture and somatic hypermutation in B cells.
Laffleur B; Lim J; Zhang W; Chen Y; Pefanis E; Bizarro J; Batista CR; Wu L; Economides AN; Wang J; Basu U
Nat Genet; 2021 Feb; 53(2):230-242. PubMed ID: 33526923
[TBL] [Abstract][Full Text] [Related]
18. Collaborative Control of Cell Cycle Progression by the RNA Exonuclease Dis3 and Ras Is Conserved Across Species.
Snee MJ; Wilson WC; Zhu Y; Chen SY; Wilson BA; Kseib C; O'Neal J; Mahajan N; Tomasson MH; Arur S; Skeath JB
Genetics; 2016 Jun; 203(2):749-62. PubMed ID: 27029730
[TBL] [Abstract][Full Text] [Related]
19. Rapid Depletion of DIS3, EXOSC10, or XRN2 Reveals the Immediate Impact of Exoribonucleolysis on Nuclear RNA Metabolism and Transcriptional Control.
Davidson L; Francis L; Cordiner RA; Eaton JD; Estell C; Macias S; Cáceres JF; West S
Cell Rep; 2019 Mar; 26(10):2779-2791.e5. PubMed ID: 30840897
[TBL] [Abstract][Full Text] [Related]
20. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.
Pertesi M; Vallée M; Wei X; Revuelta MV; Galia P; Demangel D; Oliver J; Foll M; Chen S; Perrial E; Garderet L; Corre J; Leleu X; Boyle EM; Decaux O; Rodon P; Kolb B; Slama B; Mineur P; Voog E; Le Bris C; Fontan J; Maigre M; Beaumont M; Azais I; Sobol H; Vignon M; Royer B; Perrot A; Fuzibet JG; Dorvaux V; Anglaret B; Cony-Makhoul P; Berthou C; Desquesnes F; Pegourie B; Leyvraz S; Mosser L; Frenkiel N; Augeul-Meunier K; Leduc I; Leyronnas C; Voillat L; Casassus P; Mathiot C; Cheron N; Paubelle E; Moreau P; Bignon YJ; Joly B; Bourquard P; Caillot D; Naman H; Rigaudeau S; Marit G; Macro M; Lambrecht I; Cliquennois M; Vincent L; Helias P; Avet-Loiseau H; Moreno V; Reis RM; Varkonyi J; Kruszewski M; Vangsted AJ; Jurczyszyn A; Zaucha JM; Sainz J; Krawczyk-Kulis M; Wątek M; Pelosini M; Iskierka-Jażdżewska E; Grząśko N; Martinez-Lopez J; Jerez A; Campa D; Buda G; Lesueur F; Dudziński M; García-Sanz R; Nagler A; Rymko M; Jamroziak K; Butrym A; Canzian F; Obazee O; Nilsson B; Klein RJ; Lipkin SM; McKay JD; Dumontet C
Leukemia; 2019 Sep; 33(9):2324-2330. PubMed ID: 30967618
[No Abstract] [Full Text] [Related]
[Next] [New Search]
